Another busy day on the earnings calendar kept trading erratic again on Thursday, though the S&P 500 and Nasdaq managed to clinch slight gains by the end of the session. Crude didn't have as good a day, though, plumbing fresh three-month lows. Drugmaker AstraZeneca (AZN) jumped on a better-than-expected second quarter. Sales of new drug treatments helped to offset declining revenue from cholesterol drug Crestor which has seen generic competition crop up after its patent expired. Deutsche Bank made the case for Bank of America (BAC) in a bullish note, favoring the North Carolinian institute over competitor JPMorgan (JPM) . Analysts said Bank of America is better positioned with less consumer credit risk. Match (MTCH) declined after warning investors of slowing growth. Even so, the company did manage a 41 percent increase in second-quarter profit thanks to strength in its dating app Tinder.
More from Video
Is Renewable Energy the Defensive Stock Opportunity You're Missing
AMSC CEO discusses that and China challenges.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Real Money Video Wrap: Citi Surges as View of Stability Saves Sentiment
Citi overcame a mixed print to send its stock surging on Monday.
Real Money Video Wrap: Apple Rallies as Services Segment Takes Center Stage
There is a lot of Apple news to chew on Wednesday.
Are Algos Jumping on J&J Headlines?
Are machines jumping on Johnson & Johnson's human risk headlines?
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.